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INTRODUCTION 
In this Supplement [Population-based Cancer Survival in the United States (2001-
2009): findings from the CONCORD-2 study] we provide survival estimates by race 
(black, white), state of residence at diagnosis and stage at diagnosis for nine solid tumors 
in adults1-9, and for acute lymphoblastic leukemia in children (ALL).10 Data are from 37 
statewide cancer registries that participated in the CONCORD-2 study,11 covering 80% of 
the US population. Each of the 10 cancer-specific papers includes clinical and cancer 
control perspectives. These perspectives highlight how clinical practice may have had an 
impact on population-based cancer survival trends, and how states funded by the Centers 
for Disease Control and Prevention (CDC)’s National Comprehensive Cancer Control 
Program12 can use population-based survival data, along with incidence and mortality 
data, to inform cancer control activities.13 
 
The Growing Cancer Burden 
Cancer may soon become the leading cause of death in the United States: it is already the 
leading cause in nearly half of all states.14 While the risk of dying from cancer continues 
to decrease, as measured by the age-standardized death rate, the actual number of cancer 
deaths continues to increase.15 This increase is being driven, to a large extent, by 
demographic trends related to a growing and aging U.S. population. By 2020, nearly 2 
million men, women, and children will be diagnosed with cancer annually.16 In addition, 
the number of people living with and after a cancer diagnosis (cancer survivors) will also 
increase from an estimated 14 million in 2012 to 18 million by 2022.17 Cancer survivors 
remain at risk for recurrence of their cancer, development of subsequent new cancers, and 
side-effects related to their cancer treatment.18   
 
Prevention of many of these cancers is possible through behavioral, environmental, 
policy, and clinical interventions to address the wide range of factors that put people at 
increased risk of developing cancer over their lifetime.19 However, even if all known 
effective strategies for cancer prevention were broadly implemented today, the impact on 
cancer incidence would likely not be seen for several decades, due to the long latency 
period for many cancers. The anticipated increase in the number of new cancer patients 
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and survivors poses an enormous challenge for the US health care system to meet the 
need to screen, diagnose, and treat these patients.21,22  It is also a major challenge to the 
public health community to help cancer patients meet the financial, physical and 
psychological challenges related to their cancer experience, including difficulties in 
returning to full economic activity.22,23    
 
To address the challenge of the growing cancer burden, the CDC’s Division of Cancer 
Prevention and Control (DCPC) collaborates with state and national partners to 
implement public health strategies to promote primary prevention, cancer screening, early 
diagnosis, and access to effective evidence-based treatment and survivorship care plans.12 
The challenge for the public health community is to put in place primary prevention and 
early detection strategies for the general population while meeting the growing needs of 
cancer patients and survivors.   
 
Cancer Surveillance in the US  
In the United States, cancer control activities primarily take place at the state and local 
levels, and cancer control planners need information on the unique cancer burden in their 
states. Cancer is the only reportable chronic disease in the country for which there is 
nationwide surveillance.24 There is now a population-based cancer registry in all 50 states 
and the District of Columbia.12 In addition to state support, these registries receive federal 
support from the CDC’s National Program of Cancer Registries (NPCR) and the National 
Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program. These 
registries provide a census of all people diagnosed with cancer, and along with state vital 
records offices, collect and report a basic set of information on all new cancer cases 
(incidence), deaths (including cancer-caused), the number of cancer patients alive in a 
given calendar period (prevalence) and the probability of being alive up to a given point 
in time after diagnosis (survival). 
 
Population-based cancer survival differs in a fundamental way from the survival of 
cancer patients participating in clinical trials.25,26 Population-based survival reflects the 
average survival for all cancer patients in the population, regardless of their age, sex, 
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race, health status, stage of disease, socioeconomic position, residence at diagnosis and 
access to care. As such, population-based cancer survival provides an indicator of the 
overall effectiveness of the health care system to deliver screening, early diagnosis, and 
evidenced-based treatment services and follow-up care to all people in the population 
being served.25-27  
 
The CONCORD Programme 
The CONCORD Programme at the London School of Hygiene and Tropical Medicine 
established worldwide surveillance of population-based cancer survival in 2015.11,25 The 
first CONCORD study provided a systematic comparison of survival for patients aged 
15-99 years diagnosed with a cancer of the female breast, colon, rectum, or prostate 
between 1990 and 1994.28 International differences in 5-year age-standardized survival 
were wide, even after adjustment for differences in mortality from other causes of death. 
Survival in the United States was among the highest in the world. However, the study 
reported large and consistent black and white racial disparities in survival for all four 
cancers in the United States (Table 1). For example, survival for black women diagnosed 
with breast cancer was 14% lower than survival for white women, and ranked, along with 
breast cancer survival in the United Kingdom, just above survival in eastern European 
countries, but lower than survival in northern and western European countries.  
 
The CONCORD-2 study estimated long-term survival trends among 25.7 million 
individual cancer patients in 67 countries who were diagnosed during the 15-year period 
1995-2009 with one of 10 common cancers [stomach, colon, rectum, liver, lung, female 
breast, cervix, ovary, prostate and leukaemia (including children)].11 As reported in the 
first CONCORD study, international differences in age-standardized survival were wide, 
even after adjustment for differences in mortality from other causes of death. Survival in 
the United States for most cancers was again among the highest in the world.  
 
The cancer survival estimates presented in the 10 cancer-specific papers included in this 
Supplement come from more detailed analysis of the data contributed to the CONCORD-
2 study.11 A description of the data from the 37 participating cancer registries, and the 
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rigorous and advanced statistical methods used to evaluate and analyze the data, are 
presented in an accompanying paper.29 We focused on patients diagnosed during two 
calendar periods (2001-2003 and 2004-2009), because the method used by U.S. cancer 
registries to collect and report anatomic stage (SEER Summary Stage 2000) changed 
beginning January 1, 2004. We observed 5-year survival to be high (≥80%) for breast 
cancer in women6, prostate cancer9 and acute lymphoblastic leukemia (ALL) in 
children10; moderate (50-80%) for cancers of the colon3, rectum2 and cervix7, and low 
(<50%) for cancers of the stomach1, liver4, lung5 and ovary8 (Table 1). These 
observations are consistent with those of long-term trends in survival in the United States 
for many leading cancers in both adults and children.30 The comparison of survival by 
calendar period in the cancer-specific papers in this Supplement shows that even over this 
relatively short time period, survival has improved for cancers that were highly lethal 
(stomach1, liver4, lung5, and ovary8). However, less progress was observed for cancers 
where survival was already moderate to high, likely reflecting previous gains achieved 
from screening (colon3, rectum2, breast6, and cervix7) or where treatment was already 
highly effective (ALL)10. The high survival for prostate cancer likely reflects the use of 
the prostate-specific antigen test for early detection of cancer, which was recommended 
by the American Cancer Society during this time period.31 The potential impact of over-
diagnosis was also evident in these data, where 5-year survival following a diagnosis of 
locally staged prostate cancer in black and white men9, and breast cancer in white 
women6, was close to 100%.  
 
But, as the results from this Supplement also show, the large racial disparities in cancer 
survival between blacks and whites in the United States are consistent across all 37 states 
participating in the CONCORD-2 study, and they persist over time (Table 1). With the 
exception of stomach cancer, 5-year survival was lower in black men and women than in 
white men and women for all solid tumors examined. The funnel plots in the 
accompanying articles for female breast6, colon3 and ovarian8 cancers show just how 
large and consistent these disparities were across the 37 states.  
 
7 
 
Each of the accompanying papers contains bar charts of 5-year survival for all races 
combined for each state and each calendar period, grouped by US Census Region. Some 
patterns of regional variation were observed. Survival in several Northeastern states 
tended to be somewhat higher than the pooled US estimate, while survival in several of 
the Southern states tended to be somewhat lower than the pooled US estimate. As 
expected, some variation in survival among the states was observed, likely due at least in 
part to racial and socio-economic disparities.   
 
Findings from these analyses may help explain why overall survival in the United States 
is among the highest, compared to other high-income countries, as reported in both the 
first CONCORD study and the CONCORD-2 study. The overall high percentage of 
microscopically verified cancers observed for all cancers29, and the relatively low 
percentage of patients with solid tumors for whom stage at diagnosis was unknown1-9, 
suggests that detailed clinical investigation at diagnoses was performed for most cancer 
patients diagnosed during this time period.  But the large and consistent racial disparities 
described herein are likely due to the fact that cancers diagnosed in black men and 
women tended both to be diagnosed at a later stage and to have lower survival at each 
stage of diagnosis.1-9 These disparities often appeared in the first year following 
diagnosis, suggesting that additional factors, such as co-morbidities and socio-economic 
factors related to limited access to screening, diagnosis, treatment and follow-up care, 
may be relevant. 
 
How these data can be used by cancer control programs 
Population-based survival data have been used to plan and evaluate national cancer 
control strategies in the United Kingdom.32,33  In the United States, these data can be used 
by state-based programs to help target and evaluate cancer control strategies promoting 
screening (colon, rectum, cervical, breast)12 and symptom awareness for gynecologic 
cancers (ovary).34 It should be noted that survival for women diagnosed with localized 
ovarian cancer is also high8 and future research that focuses on the development of new 
methods or modalities to detect these cancers whilst they are still at a local stage may 
well improve overall ovarian cancer survival. For cancers with low overall survival 
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(stomach, liver, lung and ovary), efforts directed at reducing cancer incidence through 
primary prevention, where such strategies exist, are likely to have the greatest impact on 
reducing the cancer burden in the longer term. 
 
Between the first CONCORD study (1990-1994) and the CONCORD-2 study (1995-
2009), survival in the United States improved for female breast, colon, rectum and 
prostate cancers (Table 1). However, 5-year survival for cancers of the colon diagnosed 
among black men and women during 2004-2009 had yet to reach the levels of survival 
seen for white men and women diagnosed during 1990-1994, some 10 to 15 years earlier. 
Similar findings were observed for breast cancer in women and rectal cancer in men, 
where survival in blacks lagged approximately 15 years behind survival in whites. If 
equal access to medical care, including screening, diagnosis and treatment services, yield 
equal outcome, regardless of race,35-37 these disparities represent a large number of 
potentially avoidable premature deaths which, in turn, impose a large economic burden 
on affected communities.38   
The findings of large, consistent and persistent racial disparities in survival should 
compel robust action. Results from the first CONCORD study showed that breast cancer 
survival in the UK was lower than in comparable European countries. This prompted the 
Department of Health in England to initiate the International Cancer Benchmarking 
Partnership study (ICBP) with the aim to examine international variation in cancer 
survival for a number of leading cancers, and to inform health policy to improve cancer 
survival through an examination of population awareness and beliefs about cancer; 
attitudes, behaviors and systems in primary care; delays in diagnosis and treatment, and 
their causes; and treatment, co-morbidities and other factors.39-42 A similar 
comprehensive and coordinated initiative at the local and state level in the United States 
might help us identify the strategies and actions needed to achieve the highest possible 
survival for all men and women diagnosed with cancer, regardless of their race, ethnicity 
and socio-economic position.  
Strengths and Limitations 
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There are inherent strengths and limitations in studies performed using data from 
population-based cancer registries. The high quality and completeness of the US data, 
and the rigor of the analytic methods used, ensured that the survival estimates reported in 
this Supplement are directly comparable between participating states. In the US, all 
cancer registries are members of the North American Association of Central Cancer 
Registries (NAACCR) and they collect and report incidence data using common 
procedures and the same data dictionary.12 The CONCORD-2 study maximized the 
comparability of the results by using a common protocol for data submission, with 
standardized quality control procedures and centralized analysis, including advanced 
statistical methods and the construction of state-, race- and sex-specific life tables of all-
cause mortality by single year of age and single calendar year, to correct for differences 
in background mortality. All participating registries met NAACCR certification criteria 
with respect to the completeness and quality of their incidence data, including 
ascertainment of cases. Therefore, the findings do not reflect case ascertainment bias 
wherein patients with very poor prognosis and shorter survival (e.g., advanced disease, 
clinical diagnosis) are less completely captured by the cancer registries than patients with 
good prognosis and longer survival. 
 
Several limitations could impact the interpretation of the findings.  While survival data 
have been shown to be comparable when death ascertainment is complete42, follow-up 
procedures among cancer registries in the United States differ depending on federal 
funding source.12 SEER registries are required to conduct active follow-up of all 
registered cases to ascertain vital status while NPCR registries are only funded to conduct 
linkage with their state vital records to obtain information on deaths that occurred within 
their state and with the CDC’s National Death Index to obtain information on deaths that 
occurred anywhere within the United States. As a result, NPCR registries may miss some 
deaths, particularly for patients who leave the United States between the time of their 
diagnosis and death, and slightly overestimate the patient’s survival time.44 This 
limitation may account for the somewhat higher survival estimates for several large 
(population) NPCR registries which were most evident in the funnel plots of highly fatal 
cancers where missing deaths could lead to an overestimate of survival.45  Second, this 
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was the first opportunity for several NPCR registries to collect and report survival data, 
which may account for some of the state variability observed, particularly in the first 
(2001-2003) calendar period. The reluctance of some medical facilities to report social 
security numbers and complete dates of birth to their state cancer registry may have 
impeded a registry’s ability to identify deaths through subsequent linkages with state and 
national death certificate files. Third, the manner in which SEER Summary Stage 2000 
data were collected and reported changed for all registries in 2004. The impact of this 
change was most evident among NPCR-funded registries, which coded stage data 
manually in the first calendar period (2001-2003) and then derived stage data in the 
second period (2004-2009); the percentage of cases with unknown stage decreased 
slightly beginning around 2004. Lastly, analyses of survival by race were restricted to 
whites and blacks, the two major racial groups in the United States, because life tables for 
other races and Hispanics were not available.  
 
Future Plans 
The CONCORD-3 study is in progress. It will update world-wide surveillance of cancer 
survival trends to include patients diagnosed through 2014.26 It will include 15 
malignancies that collectively represent 75% of the global cancer burden: esophagus, 
stomach, colon, rectum, liver, pancreas, lung, melanoma, breast (women), cervix, ovary 
and prostate in adults (15-99 years), and brain tumors, lymphomas and leukemias in both 
adults and children (0-14 years). The US contribution is expected to cover 44 states and 
up to 90% of the national population. 
 
Conclusion  
The quality of the CONCORD-2 data, the rigorous statistical methods used and the large 
population coverage provide a broad and comprehensive overview of trends in survival 
among cancer patients diagnosed up to 2009. They provide a valuable contribution to 
public health and cancer control in the United States. These data benchmark the status of 
population-based cancer survival immediately prior to the implementation of the 
Affordable Care Act in 2010.  Further improvements in survival may result from 
collaborations with state and national partners to implement public health strategies to 
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promote cancer screening, early diagnosis, access to effective evidence-based treatment 
(including personalized cancer care and targeted therapies), and follow-up care. The 
Division of Cancer Prevention and Control can help improve access to timely diagnosis 
and treatment through its screening programs, awareness campaigns and by facilitating 
the implementation of long-term survivorship care plans.12    
 
The challenge will be to ensure that everyone diagnosed with cancer in the United States 
benefits equally from advances in diagnosis and treatment. 
12 
 
References 
1. Jim MA, Pinheiro PS, Carreira H, Espey DK, Wiggins CL, Weir HK. 
Stomach cancer survival in the United States by race and stage (2001-2009):  
findings from the CONCORD-2 study. Cancer. 2017;xx:yy-yy. 
2. Joseph DA, Johnson CJ, White A, Wu M, Coleman MP. Rectal Cancer Survival 
in the United States by Race and Stage (2001-2009): Findings from the 
CONCORD-2 study. Cancer. 2017;xx:yy-yy. 
3. White A, Joseph DA, Rim SH, Johnson CJ, Coleman MP, Allemani C. Colon 
Cancer Survival in the United States by Race and Stage (2001-2009): findings 
from the CONCORD -2 study. Cancer. 2017;xx:yy-yy. 
4. Momin BR, Pinheiro PS, Carreira H, Li C, Weir HK. Liver cancer survival in the 
United States by race and stage (2001-2009): findings from the CONCORD -2 
study. Cancer. 2017;xx:yy-yy. 
5. Richards TB, Henley SJ, Puckett MC, Weir HK, Huang B, Tucker TC, Allemani 
C. Lung cancer survival in the United States by race and stage (2001–2009): 
findings from the CONCORD–2 study. Cancer. 2017; xx: yy-yy. 
6. Miller JW, Lee Smith J, Ryerson AB, Tucker TC, Allemani C. Disparities in 
breast cancer survival in the United States (2001-2009): findings from the 
CONCORD-2 study. Cancer. 2017;xx:pp-pp. 
7. Benard V, Watson M, Saraiya M, Harewood R, Townsend JS, Stroup AM, Weir 
HK, Allemani C. Cervical cancer survival in the United States by race and stage 
(2001-2009): findings from the CONCORD -2 study. Cancer. 2017;xx:yy-yy. 
8. Stewart SL, Harewood R, Matz M, Rim SH, Sabatino SA, Ward KC, Weir HK.  
Population-Based Ovarian Cancer Survival in the United States from 2001-2009. 
Cancer. 2017;xx:pp-pp.  
9. Steele CB, Li J, Huang B, Weir HK. Prostate cancer survival in the United States 
by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer. 
2017;xx:pp- pp. 
10. Tai E, Ward KC, Bonaventure A, Siegel D, Coleman MP. Survival among 
children diagnosed with acute lymphoblastic leukemia in the United States by 
13 
 
race and age, 2001-2009: findings from the CONCORD-2 Study. Cancer. 
2017;xx:pp-pp. 
11. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, 
Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e 
Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, 
Bielska-Lasota M, Storm H, Tucker TC, Coleman MP, CONCORD Working 
Group. Global surveillance of cancer survival 1995-2009: analysis of individual 
data for 25,676,887 patients from 279 population-based registries in 67 countries 
(CONCORD-2). Lancet. 2015;385:977-1010. 
12. White MC, Babcock F, Hayes NS, Mariotto AB, Wong FL, Kohler BA, Weir HK. 
The History and Use of Cancer Registry Data by Public Health Cancer Control 
Programs in the United States. Cancer. 2017;xx:yy-yy. 
13. Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S. When do changes in cancer 
survival mean progress? The insight from population incidence and mortality. JNCI 
Monogr. 2014 Nov;2014(49):187-97 
14. Weir HK, Anderson RN, Coleman King SM, Soman A, Thompson TO, Hong Y, 
Møller B, Leadbetter S. Heart Disease and Cancer Deaths — Trends and 
Projections in the United States, 1969–2020. Pediatr Infect Dis J. November 17.  
15. Weir HK, Thompson TD, Soman A, Møller B, Leadbetter S, White MC. Peer 
Reviewed: Meeting the Healthy People 2020 Objectives to Reduce Cancer 
Mortality. Prev Chronic Dis. 2015;12:E104. 
16. Weir HK, Thompson TD, Soman A, Møller B, Leadbetter S. The past, present, and 
future of cancer incidence in the United States: 1975 through 2020. Cancer. 
2015;121:1827-37. 
17. de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, 
Scoppa S, Hachey M, Rowland JH. Cancer survivors in the United States: 
prevalence across the survivorship trajectory and implications for care. Cancer 
Epidemiol Biomarkers Prev. 2013;22:561-70. 
18. White MC, Hayes NS, Richardson LC. Public Health's Future Role in Cancer 
Survivorship. Am J Prev Med. 2015;49(6 suppl 5):S550-3.  
19. Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer 
14 
 
prevention. Sci Transl Med. 2012;4:127.  
20. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the 
United States: estimates, projections, and future research. Cancer Epidemiol 
Biomarkers Prev. 2011;10:2006-14. 
21. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost 
of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-
28. 
22. Buchanan ND, Houston K, Richardson LC. The essential role of public health in 
preventing disease, prolonging life, and promoting health of cancer survivors. Am 
J Prev Med. 2015;49(6):S467–69. 
23. Buchanan ND, Dasari S, Rodriguez JL, Smith JL, Hodgson ME, Weinberg CR, 
Sandler DP. Post-treatment neurocognition and psychosocial care among breast 
cancer survivors. Am J Prev Med. 2015;49(6 suppl 5):S498–S508. 
24. CDC. Summary of notifiable noninfectious conditions and disease outbreaks—
United States. MMWR Morb Mortal Wkly Rep 2013;62(54). 
25. Coleman MP. Cancer survival: global surveillance will stimulate health policy 
and improve equity. Lancet. 2014;383:564-73. 
26. Allemani C, Coleman MP. Public health surveillance of cancer survival: in the US 
and world-wide: the contribution of the CONCORD programme. Cancer. 
2017;xx:yy-yy.  
27. Karanikolos M, Ellis L, Coleman MP, McKee M. Health systems performance and 
cancer outcomes. Natl Cancer Inst Monogr. 2013;46:7-12. 
28. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili 
P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, 
Tsukuma H, Koifman S, E Silva GA, Francisci S, Santaquilani M, Verdecchia A, 
Storm HH, Young JL. CONCORD Working Group. Cancer survival in five 
continents: a worldwide population-based study (CONCORD). Lancet Oncol. 
2008;9:730-56. 
29. Allemani C, Harewood R, Johnson CJ, Carreira H, Spika D, Bonaventure A, Ward 
KC, Weir HK, Coleman MP. Population-based cancer survival in the US: data, 
quality control and statistical methods. Cancer. 2017;xx:yy-yy. 
15 
 
30. Ahmedin J, Ward EM, Johnson CJ, et al.  Annual Report to the Nation on the 
Status of Cancer, 1975–2013, Featuring Survival. J Natl Cancer Inst. 2017 Sep 
1;109(9). doi: 10.1093/jnci/djx030. 
31. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society 
guidelines for the early detection of cancer: update of early detection guidelines for 
prostate, colorectal, and endometrial cancers. Also: update 2001—testing for early 
lung cancer detection. CA Cancer J Clin. 2001;51:38-75. 
32. Rachet B, Ellis L, Maringe C, Chu T, Nur U, Quaresma M, Shah A, Walters S, 
Woods L, Forman D, Coleman MP. Socioeconomic inequalities in cancer survival 
in England after the NHS cancer plan. Br J Cancer. 2010;103:446-53. 
33. Walters S, Benitez-Majano S, Muller P, Coleman MP, Allemani C, Butler J, 
Peake M, Guren MG, Glimelius B, Bergström S, Påhlman L, Rachet B. Is 
England closing the international gap in cancer survival? Br J Cancer. 
2015;113(5):848-60.  
34. Puckett MC, Townsend JS, Gelb CA, Hager P, Conlon A, Stewart SL Ovarian 
Cancer Knowledge in Women and Providers Following Education with Inside 
Knowledge Campaign Materials. J Cancer Educ. 2017 Jun 24. doi: 
10.1007/s13187-017-1245-0. 
35. Brawley OW. Is race really a negative prognostic factor for cancer? J Natl Cancer 
Inst. 2009;101:970-1. 
36. Brawley OW. Lung cancer and race: equal treatment yields equal outcome among 
equal patients, but there is no equal treatment. J Clin Oncol. 2006;24:332-3. 
37. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of 
blacks and whites after a cancer diagnosis. J Am Med Assoc. 2002;287:2106-13. 
38. Weir HK, Li C, Henley SJ, Joseph DA. Estimating years of life and productivity 
lost from potentially avoidable colorectal cancer deaths in the United States in 
counties with lower educational attainment (submitted to CEBP).  
39. Butler J, Foot C, Bomb M, Hiom S, Coleman MP, Bryant H, Vedsted P, Hanson 
J, Richards M, ICBP Working Group. The International Cancer Benchmarking 
Partnership: an international collaboration to inform cancer policy in Australia, 
Canada, Denmark, Norway, Sweden and the United Kingdom. Health Policy. 
16 
 
2013;112:148-55. 
40. Weller D, Vedsted P, Anandan C, Zalounina A, Fourkala EO, Desai R, Liston W, 
Jensen H, Barisic A, Gavin A, Grunfeld E, Lambe M, Law RJ, Malmberg M, 
Neal RD, Kalsi J, Turner D, White V, Bomb M, Menon U, ICBP Module 4 
Working Group*. An investigation of routes to cancer diagnosis in 10 
international jurisdictions, as part of the International Cancer Benchmarking 
Partnership: survey development and implementation. BMJ Open. 2016. 
25;6(7):e009641. 
41. Brown S, Castelli M, Hunter DJ, Erskine J, Vedsted P, Foot C, Rubin G. How 
might healthcare systems influence speed of cancer diagnosis: a narrative review. 
Soc Sci Med. 2014;116:56-63.  
42. Rose PW, Rubin G, Perera-Salazar R, Almberg SS, Barisic A, Dawes M, 
Grunfeld E, Hart N, Neal RD, Pirotta M, Sisler J, Konrad G, Toftegaard BS, 
Thulesius H, Vedsted P, Young J, Hamilton W. ICBP Module 3 Working 
Group*.; ICBP Module 3 Working Group. Explaining variation in cancer survival 
between 11 jurisdictions in the International Cancer Benchmarking Partnership: a 
primary care vignette survey. BMJ Open. 2015;27:5(5):e007212. 
43. Weir HK, Johnson CJ, Mariotto AB, Turner D, Wilson RJ, Nishri D, Ward KC. 
Evaluation of North American Association of Central Cancer Registries' 
(NAACCR) data for use in population-based cancer survival studies. J Natl 
Cancer Inst Monogr. 2014;49:198-209. 
44. Pinheiro PS, Morris CR, Liu L, Bungum TJ, Altekruse SF. The impact of follow-
up type and missed deaths on population-based cancer survival studies for 
Hispanics and Asians. J Natl Cancer Inst Monogr. 2014;49:210-7.  
45. Johnson CJ, Weir HK, Fink AK, German RR, Finch JL, Rycroft RK, Yin D. 
Accuracy of Cancer Mortality Study Group. The impact of National Death Index 
linkages on population-based cancer survival rates in the United States. Cancer 
Epidemiol. 2013;37:20-8. 
 
 
 
17 
 
CONCORD Working Group United States: JT George, X Shen (Alabama Statewide Cancer Registry); 
JT Brockhouse, DK O'Brien (Alaska Cancer Registry); KC Ward (Georgia Comprehensive Cancer 
Registry; Metropolitan Atlanta Registry); L Almon (Metropolitan Atlanta Registry); J Bates (California 
State Cancer Registry); R Rycroft (Colorado Central Cancer Registry); L Mueller, C Phillips (Connecticut 
Tumor Registry); H Brown, B Cromartie (Delaware Cancer Registry); A Schwartz, F Vigneau 
(Metropolitan Detroit Cancer Surveillance System); JA MacKinnon, B Wohler (Florida Cancer Data 
System); AR Bayakly (Georgia Comprehensive Cancer Registry); CA Clarke, SL Glaser (Greater Bay 
Area Cancer Registry); D West (Cancer Registry of Greater California); MD Green, BY Hernandez 
(Hawaii Tumor Registry); CJ Johnson, D Jozwik (Cancer Data Registry of Idaho); ME Charlton, CF 
Lynch (State Health Registry of Iowa); B Huang, TC Tucker* (Kentucky Cancer Registry); D Deapen, L 
Liu (Los Angeles Cancer Surveillance Program); MC Hsieh, XC Wu (Louisiana Tumor Registry); K Stern 
(Maryland Cancer Registry); ST Gershman, RC Knowlton (Massachusetts Cancer Registry); J Alverson, 
GE Copeland (Michigan State Cancer Surveillance Program); DB Rogers (Mississippi Cancer Registry); 
D Lemons, LL Williamson (Montana Central Tumor Registry); M Hood (Nebraska Cancer Registry); GM 
Hosain, JR Rees (New Hampshire State Cancer Registry); KS Pawlish, AM Stroup (New Jersey State 
Cancer Registry); C Key, CL Wiggins (New Mexico Tumor Registry); AR Kahn, MJ Schymura (New 
York State Cancer Registry); G Leung, C Rao (North Carolina Central Cancer Registry); L Giljahn, B 
Warther (Ohio Cancer Incidence Surveillance System); A Pate (Oklahoma Central Cancer Registry); M 
Patil, SS Schubert (Oregon State Cancer Registry); JJ Rubertone, SJ Slack (Pennsylvania Cancer 
Registry); JP Fulton, DL Rousseau (Rhode Island Cancer Registry); TA Janes, SM Schwartz (Seattle 
Cancer Surveillance System); SW Bolick, DM Hurley (South Carolina Central Cancer Registry); J 
Richards, MA Whiteside (Tennessee Cancer Registry); LM Nogueira (Texas Cancer Registry); K Herget, 
C Sweeney (Utah Cancer Registry); J Martin, S Wang (Virginia Cancer Registry); DG Harrelson, MB 
Keitheri Cheteri (Washington State Cancer Registry); S Farley, AG Hudson (West Virginia Cancer 
Registry); R Borchers, L Stephenson (Wisconsin Department of Health Services); JR Espinoza (Wyoming 
Cancer Surveillance Program); HK Weir (Centers for Disease Control and Prevention); BK Edwards 
(National Cancer Institute) 
 
  
18 
 
Table 1     5-year age-standardized population-based survival by calendar period of diagnosis, cancer 
site and race (black, white).  
Site  Sex 
CONCORD 
(1990-94) a 
CONCORD 2 
(2004-2009) b 
  Black White Difference Black White Difference 
Stomach Both  NA NA NA 28.3 28.0 0.3 
Colon Men  51.5 60.5 -9.0 54.5 64.5 -10.0 
 Women 51.0 60.8 -9.8 58.6 66.5 -7.9 
Rectum  Men  47.4 57.3 -9.9 53.6 62.8 -9.2 
 Women 49.4 60.4 -11.0 61.8 66.2 -4.4 
Liver Both  NA NA NA 11.4 14.3 -2.9 
Lung Both  NA NA NA 14.9 19.4 -4.5 
Breast  Women 70.9 84.7 -13.8 78.4 89.7 -11.3 
Cervix Women NA NA NA 55.5 63.5 -8.0 
Ovary Women NA NA NA 31.1 41.7 -10.6 
Prostate Men 85.8 92.4 -6.6 92.7 96.9 -4.2 
ALL  Both  NA NA NA 83.6 88.6 -5.0 
 
NA – not applicable. 
Source:  a Coleman et al. 2008 (ref # 28) ; b Allemani et al. 2017 (ref #11, 29).  
 
 
 
 
 
 
 
 
 
